Skip to main
VCEL

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp's stock is positively influenced by the anticipated growth in its MACI product, with projected volume increasing in the low-to-mid teens alongside an annual average selling price (ASP) increase of approximately 300 to 500 basis points. This growth trajectory is supported by estimates indicating a year-over-year revenue increase for MACI of around 21.2% in fiscal year 2026, fueled by a favorable combination of volume and pricing dynamics. Furthermore, positive financial performance is evident as 4Q revenue is expected to reach $84.8 million, representing a notable 26% quarter-over-quarter growth.

Bears say

Vericel Corp faces a negative outlook primarily due to revised revenue expectations for its MACI product, which have been lowered by approximately 200 basis points for fiscal years 2026 and 2027. There are significant risks associated with slower adoption rates for MACI and MACI Arthro, as well as challenges in burn care sales and potential disruptions from sales force expansion. Additionally, any failure to meet top-line revenue expectations may result in the company's shares declining to historically low valuation levels.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.